Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Abstract Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.

Bibliographic Details
Main Authors: Catherine Percy, Thomas Schubert, Christine Galant, Thomas Kirchgesner, Filomena Mazzeo
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Clinical Case Reports
Subjects:
larotrectinib
neoadjuvant
NTRK gene fusions
soft tissue sarcoma
Online Access:https://doi.org/10.1002/ccr3.3878

Similar Items

Similar Items